Evaluation of the safety and efficacy of using human menstrual blood‐derived mesenchymal stromal cells in treating severe and critically ill COVID‐19 patients: An exploratory clinical trial

The coronavirus disease 2019 (COVID‐19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) was identified in December 2019 and has subsequently spread worldwide. Currently, there is no effective method to cure COVID‐19. Mesenchymal stromal cells (MSCs) may be able to effectively...

Full description

Saved in:
Bibliographic Details
Published inClinical and Translational Medicine Vol. 11; no. 2; pp. e297 - n/a
Main Authors Xu, Xiaowei, Jiang, Wanli, Chen, Lijun, Xu, Zhenyu, Zhang, Qiang, Zhu, Mengfei, Ye, Peng, Li, Hang, Yu, Liang, Zhou, Xiaoyang, Zhou, Chenliang, Chen, Xiaobei, Zheng, Xiaoqin, Xu, Kaijin, Cai, Hongliu, Zheng, Shufa, Jiang, Wubian, Wu, Xiaojun, Li, Dong, Chen, Lu, Luo, Qingqing, Wang, Yingyan, Qu, Jingjing, Li, Yifei, Zheng, Wendi, Jiang, Yingan, Tang, Lingling, Xiang, Charlie, Li, Lanjuan
Format Journal Article Web Resource
LanguageEnglish
Published United States John Wiley & Sons, Inc 01.02.2021
John Wiley and Sons Inc
Wiley
Subjects
Adenoviruses
Adolescent
Adult
Aged
Allografts
Clinical medicine
Clinical trials
coronavirus disease 2019 (COVID‐19)
Coronaviruses
COVID-19 - blood
COVID-19 - mortality
COVID-19 - therapy
COVID-19 vaccines
Critical Illness
Disease transmission
Disease-Free Survival
Dyspnea
Epidemics
Female
Hospitals
Humans
Infections
Male
Medical research
Menstruation
Mesenchymal Stem Cell Transplantation
Mesenchymal Stem Cells
mesenchymal stromal cells
Middle Aged
safety and efficacy
SARS-CoV-2 - metabolism
Severe acute respiratory syndrome coronavirus 2
severe and critical patients
Severity of Illness Index
Stem cells
Survival Rate
China
safety and efficacy
severe and critical patients
coronavirus disease 2019 (COVID-19)
mesenchymal stromal cells
Online AccessGet full text

Cover

Abstract The coronavirus disease 2019 (COVID‐19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) was identified in December 2019 and has subsequently spread worldwide. Currently, there is no effective method to cure COVID‐19. Mesenchymal stromal cells (MSCs) may be able to effectively treat COVID‐19, especially for severe and critical patients. Menstrual blood‐derived MSCs have recently received much attention due to their superior proliferation ability and their lack of ethical problems. Forty‐four patients were enrolled from January to April 2020 in a multicenter, open‐label, nonrandomized, parallel‐controlled exploratory trial. Twenty‐six patients received allogeneic, menstrual blood‐derived MSC therapy, and concomitant medications (experimental group), and 18 patients received only concomitant medications (control group). The experimental group was treated with three infusions totaling 9 × 107 MSCs, one infusion every other day. Primary and secondary endpoints related to safety and efficacy were assessed at various time points during the 1‐month period following MSC infusion. Safety was measured using the frequency of treatment‐related adverse events (AEs). Patients in the MSC group showed significantly lower mortality (7.69% died in the experimental group vs 33.33% in the control group; P = .048). There was a significant improvement in dyspnea while undergoing MSC infusion on days 1, 3, and 5. Additionally, SpO2 was significantly improved following MSC infusion, and chest imaging results were improved in the experimental group in the first month after MSC infusion. The incidence of most AEs did not differ between the groups. MSC‐based therapy may serve as a promising alternative method for treating severe and critical COVID‐19. Menstrual blood‐derived MSC transplantation significantly lowers the mortality of severe and critical SARS‐CoV‐2‐induced COVID‐19. This prospective and systematic report assessed the ability of menstrual blood‐derived MSCs to treat both severe and critically ill COVID‐19 patients. MSC‐based therapy may serve in future clinical applications as an alternative way for the treatment of COVID‐19
AbstractList The coronavirus disease 2019 (COVID‐19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) was identified in December 2019 and has subsequently spread worldwide. Currently, there is no effective method to cure COVID‐19. Mesenchymal stromal cells (MSCs) may be able to effectively treat COVID‐19, especially for severe and critical patients. Menstrual blood‐derived MSCs have recently received much attention due to their superior proliferation ability and their lack of ethical problems. Forty‐four patients were enrolled from January to April 2020 in a multicenter, open‐label, nonrandomized, parallel‐controlled exploratory trial. Twenty‐six patients received allogeneic, menstrual blood‐derived MSC therapy, and concomitant medications (experimental group), and 18 patients received only concomitant medications (control group). The experimental group was treated with three infusions totaling 9 × 107 MSCs, one infusion every other day. Primary and secondary endpoints related to safety and efficacy were assessed at various time points during the 1‐month period following MSC infusion. Safety was measured using the frequency of treatment‐related adverse events (AEs). Patients in the MSC group showed significantly lower mortality (7.69% died in the experimental group vs 33.33% in the control group; P = .048). There was a significant improvement in dyspnea while undergoing MSC infusion on days 1, 3, and 5. Additionally, SpO2 was significantly improved following MSC infusion, and chest imaging results were improved in the experimental group in the first month after MSC infusion. The incidence of most AEs did not differ between the groups. MSC‐based therapy may serve as a promising alternative method for treating severe and critical COVID‐19.
The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified in December 2019 and has subsequently spread worldwide. Currently, there is no effective method to cure COVID-19. Mesenchymal stromal cells (MSCs) may be able to effectively treat COVID-19, especially for severe and critical patients. Menstrual blood-derived MSCs have recently received much attention due to their superior proliferation ability and their lack of ethical problems. Forty-four patients were enrolled from January to April 2020 in a multicenter, open-label, nonrandomized, parallel-controlled exploratory trial. Twenty-six patients received allogeneic, menstrual blood-derived MSC therapy, and concomitant medications (experimental group), and 18 patients received only concomitant medications (control group). The experimental group was treated with three infusions totaling 9 × 107 MSCs, one infusion every other day. Primary and secondary endpoints related to safety and efficacy were assessed at various time points during the 1-month period following MSC infusion. Safety was measured using the frequency of treatment-related adverse events (AEs). Patients in the MSC group showed significantly lower mortality (7.69% died in the experimental group vs 33.33% in the control group; P = .048). There was a significant improvement in dyspnea while undergoing MSC infusion on days 1, 3, and 5. Additionally, SpO2 was significantly improved following MSC infusion, and chest imaging results were improved in the experimental group in the first month after MSC infusion. The incidence of most AEs did not differ between the groups. MSC-based therapy may serve as a promising alternative method for treating severe and critical COVID-19.The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified in December 2019 and has subsequently spread worldwide. Currently, there is no effective method to cure COVID-19. Mesenchymal stromal cells (MSCs) may be able to effectively treat COVID-19, especially for severe and critical patients. Menstrual blood-derived MSCs have recently received much attention due to their superior proliferation ability and their lack of ethical problems. Forty-four patients were enrolled from January to April 2020 in a multicenter, open-label, nonrandomized, parallel-controlled exploratory trial. Twenty-six patients received allogeneic, menstrual blood-derived MSC therapy, and concomitant medications (experimental group), and 18 patients received only concomitant medications (control group). The experimental group was treated with three infusions totaling 9 × 107 MSCs, one infusion every other day. Primary and secondary endpoints related to safety and efficacy were assessed at various time points during the 1-month period following MSC infusion. Safety was measured using the frequency of treatment-related adverse events (AEs). Patients in the MSC group showed significantly lower mortality (7.69% died in the experimental group vs 33.33% in the control group; P = .048). There was a significant improvement in dyspnea while undergoing MSC infusion on days 1, 3, and 5. Additionally, SpO2 was significantly improved following MSC infusion, and chest imaging results were improved in the experimental group in the first month after MSC infusion. The incidence of most AEs did not differ between the groups. MSC-based therapy may serve as a promising alternative method for treating severe and critical COVID-19.
Abstract The coronavirus disease 2019 (COVID‐19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) was identified in December 2019 and has subsequently spread worldwide. Currently, there is no effective method to cure COVID‐19. Mesenchymal stromal cells (MSCs) may be able to effectively treat COVID‐19, especially for severe and critical patients. Menstrual blood‐derived MSCs have recently received much attention due to their superior proliferation ability and their lack of ethical problems. Forty‐four patients were enrolled from January to April 2020 in a multicenter, open‐label, nonrandomized, parallel‐controlled exploratory trial. Twenty‐six patients received allogeneic, menstrual blood‐derived MSC therapy, and concomitant medications (experimental group), and 18 patients received only concomitant medications (control group). The experimental group was treated with three infusions totaling 9 × 10 7 MSCs, one infusion every other day. Primary and secondary endpoints related to safety and efficacy were assessed at various time points during the 1‐month period following MSC infusion. Safety was measured using the frequency of treatment‐related adverse events (AEs). Patients in the MSC group showed significantly lower mortality (7.69% died in the experimental group vs 33.33% in the control group; P  = .048). There was a significant improvement in dyspnea while undergoing MSC infusion on days 1, 3, and 5. Additionally, SpO 2 was significantly improved following MSC infusion, and chest imaging results were improved in the experimental group in the first month after MSC infusion. The incidence of most AEs did not differ between the groups. MSC‐based therapy may serve as a promising alternative method for treating severe and critical COVID‐19.
The coronavirus disease 2019 (COVID‐19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) was identified in December 2019 and has subsequently spread worldwide. Currently, there is no effective method to cure COVID‐19. Mesenchymal stromal cells (MSCs) may be able to effectively treat COVID‐19, especially for severe and critical patients. Menstrual blood‐derived MSCs have recently received much attention due to their superior proliferation ability and their lack of ethical problems. Forty‐four patients were enrolled from January to April 2020 in a multicenter, open‐label, nonrandomized, parallel‐controlled exploratory trial. Twenty‐six patients received allogeneic, menstrual blood‐derived MSC therapy, and concomitant medications (experimental group), and 18 patients received only concomitant medications (control group). The experimental group was treated with three infusions totaling 9 × 10 7 MSCs, one infusion every other day. Primary and secondary endpoints related to safety and efficacy were assessed at various time points during the 1‐month period following MSC infusion. Safety was measured using the frequency of treatment‐related adverse events (AEs). Patients in the MSC group showed significantly lower mortality (7.69% died in the experimental group vs 33.33% in the control group; P  = .048). There was a significant improvement in dyspnea while undergoing MSC infusion on days 1, 3, and 5. Additionally, SpO 2 was significantly improved following MSC infusion, and chest imaging results were improved in the experimental group in the first month after MSC infusion. The incidence of most AEs did not differ between the groups. MSC‐based therapy may serve as a promising alternative method for treating severe and critical COVID‐19. Menstrual blood‐derived MSC transplantation significantly lowers the mortality of severe and critical SARS‐CoV‐2‐induced COVID‐19. This prospective and systematic report assessed the ability of menstrual blood‐derived MSCs to treat both severe and critically ill COVID‐19 patients. MSC‐based therapy may serve in future clinical applications as an alternative way for the treatment of COVID‐19
Abstract The coronavirus disease 2019 (COVID‐19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) was identified in December 2019 and has subsequently spread worldwide. Currently, there is no effective method to cure COVID‐19. Mesenchymal stromal cells (MSCs) may be able to effectively treat COVID‐19, especially for severe and critical patients. Menstrual blood‐derived MSCs have recently received much attention due to their superior proliferation ability and their lack of ethical problems. Forty‐four patients were enrolled from January to April 2020 in a multicenter, open‐label, nonrandomized, parallel‐controlled exploratory trial. Twenty‐six patients received allogeneic, menstrual blood‐derived MSC therapy, and concomitant medications (experimental group), and 18 patients received only concomitant medications (control group). The experimental group was treated with three infusions totaling 9 × 107 MSCs, one infusion every other day. Primary and secondary endpoints related to safety and efficacy were assessed at various time points during the 1‐month period following MSC infusion. Safety was measured using the frequency of treatment‐related adverse events (AEs). Patients in the MSC group showed significantly lower mortality (7.69% died in the experimental group vs 33.33% in the control group; P = .048). There was a significant improvement in dyspnea while undergoing MSC infusion on days 1, 3, and 5. Additionally, SpO2 was significantly improved following MSC infusion, and chest imaging results were improved in the experimental group in the first month after MSC infusion. The incidence of most AEs did not differ between the groups. MSC‐based therapy may serve as a promising alternative method for treating severe and critical COVID‐19.
The coronavirus disease 2019 (COVID‐19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) was identified in December 2019 and has subsequently spread worldwide. Currently, there is no effective method to cure COVID‐19. Mesenchymal stromal cells (MSCs) may be able to effectively treat COVID‐19, especially for severe and critical patients. Menstrual blood‐derived MSCs have recently received much attention due to their superior proliferation ability and their lack of ethical problems. Forty‐four patients were enrolled from January to April 2020 in a multicenter, open‐label, nonrandomized, parallel‐controlled exploratory trial. Twenty‐six patients received allogeneic, menstrual blood‐derived MSC therapy, and concomitant medications (experimental group), and 18 patients received only concomitant medications (control group). The experimental group was treated with three infusions totaling 9 × 107 MSCs, one infusion every other day. Primary and secondary endpoints related to safety and efficacy were assessed at various time points during the 1‐month period following MSC infusion. Safety was measured using the frequency of treatment‐related adverse events (AEs). Patients in the MSC group showed significantly lower mortality (7.69% died in the experimental group vs 33.33% in the control group; P = .048). There was a significant improvement in dyspnea while undergoing MSC infusion on days 1, 3, and 5. Additionally, SpO2 was significantly improved following MSC infusion, and chest imaging results were improved in the experimental group in the first month after MSC infusion. The incidence of most AEs did not differ between the groups. MSC‐based therapy may serve as a promising alternative method for treating severe and critical COVID‐19. Menstrual blood‐derived MSC transplantation significantly lowers the mortality of severe and critical SARS‐CoV‐2‐induced COVID‐19. This prospective and systematic report assessed the ability of menstrual blood‐derived MSCs to treat both severe and critically ill COVID‐19 patients. MSC‐based therapy may serve in future clinical applications as an alternative way for the treatment of COVID‐19
The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified in December 2019 and has subsequently spread worldwide. Currently, there is no effective method to cure COVID-19. Mesenchymal stromal cells (MSCs) may be able to effectively treat COVID-19, especially for severe and critical patients. Menstrual blood-derived MSCs have recently received much attention due to their superior proliferation ability and their lack of ethical problems. Forty-four patients were enrolled from January to April 2020 in a multicenter, open-label, nonrandomized, parallel-controlled exploratory trial. Twenty-six patients received allogeneic, menstrual blood-derived MSC therapy, and concomitant medications (experimental group), and 18 patients received only concomitant medications (control group). The experimental group was treated with three infusions totaling 9 × 10 MSCs, one infusion every other day. Primary and secondary endpoints related to safety and efficacy were assessed at various time points during the 1-month period following MSC infusion. Safety was measured using the frequency of treatment-related adverse events (AEs). Patients in the MSC group showed significantly lower mortality (7.69% died in the experimental group vs 33.33% in the control group; P = .048). There was a significant improvement in dyspnea while undergoing MSC infusion on days 1, 3, and 5. Additionally, SpO was significantly improved following MSC infusion, and chest imaging results were improved in the experimental group in the first month after MSC infusion. The incidence of most AEs did not differ between the groups. MSC-based therapy may serve as a promising alternative method for treating severe and critical COVID-19.
Author Chen, Xiaobei
Xu, Kaijin
Jiang, Wubian
Tang, Lingling
Li, Lanjuan
Zheng, Shufa
Zhu, Mengfei
Zheng, Xiaoqin
Li, Yifei
Xu, Zhenyu
Chen, Lijun
Xiang, Charlie
Wang, Yingyan
Li, Hang
Zhang, Qiang
Yu, Liang
Zhou, Chenliang
Luo, Qingqing
Cai, Hongliu
Jiang, Wanli
Ye, Peng
Jiang, Yingan
Zhou, Xiaoyang
Li, Dong
Qu, Jingjing
Xu, Xiaowei
Chen, Lu
Wu, Xiaojun
Zheng, Wendi
AuthorAffiliation 5 Department of Respiratory Disease Thoracic Disease Centre The First Affiliated Hospital College of Medicine Zhejiang University Hangzhou Zhejiang P. R. China
1 State Key Laboratory for Diagnosis and Treatment of Infectious Diseases National Clinical Research Center for Infectious Diseases Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases The First Affiliated Hospital College of Medicine Zhejiang University Hangzhou Zhejiang P. R. China
4 Shulan (Hangzhou) Hospital, Zhejiang Shuren University Shulan International Medical College Hangzhou Zhejiang P. R. China
2 Department of Infectious Diseases Renmin Hospital of Wuhan University Wuhan Hebei P.R. China
3 Innovative Precision Medicine (IPM) Group Hangzhou Zhejiang P. R. China
AuthorAffiliation_xml – name: 1 State Key Laboratory for Diagnosis and Treatment of Infectious Diseases National Clinical Research Center for Infectious Diseases Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases The First Affiliated Hospital College of Medicine Zhejiang University Hangzhou Zhejiang P. R. China
– name: 3 Innovative Precision Medicine (IPM) Group Hangzhou Zhejiang P. R. China
– name: 2 Department of Infectious Diseases Renmin Hospital of Wuhan University Wuhan Hebei P.R. China
– name: 5 Department of Respiratory Disease Thoracic Disease Centre The First Affiliated Hospital College of Medicine Zhejiang University Hangzhou Zhejiang P. R. China
– name: 4 Shulan (Hangzhou) Hospital, Zhejiang Shuren University Shulan International Medical College Hangzhou Zhejiang P. R. China
Author_xml – sequence: 1
  givenname: Xiaowei
  surname: Xu
  fullname: Xu, Xiaowei
  organization: Zhejiang University
– sequence: 2
  givenname: Wanli
  surname: Jiang
  fullname: Jiang, Wanli
  organization: Renmin Hospital of Wuhan University
– sequence: 3
  givenname: Lijun
  orcidid: 0000-0001-9374-6466
  surname: Chen
  fullname: Chen, Lijun
  organization: Zhejiang University
– sequence: 4
  givenname: Zhenyu
  surname: Xu
  fullname: Xu, Zhenyu
  organization: Innovative Precision Medicine (IPM) Group
– sequence: 5
  givenname: Qiang
  surname: Zhang
  fullname: Zhang, Qiang
  organization: Innovative Precision Medicine (IPM) Group
– sequence: 6
  givenname: Mengfei
  surname: Zhu
  fullname: Zhu, Mengfei
  organization: Shulan (Hangzhou) Hospital, Zhejiang Shuren University Shulan International Medical College
– sequence: 7
  givenname: Peng
  surname: Ye
  fullname: Ye, Peng
  organization: Renmin Hospital of Wuhan University
– sequence: 8
  givenname: Hang
  surname: Li
  fullname: Li, Hang
  organization: Innovative Precision Medicine (IPM) Group
– sequence: 9
  givenname: Liang
  orcidid: 0000-0003-1007-3951
  surname: Yu
  fullname: Yu, Liang
  organization: Zhejiang University
– sequence: 10
  givenname: Xiaoyang
  surname: Zhou
  fullname: Zhou, Xiaoyang
  organization: Renmin Hospital of Wuhan University
– sequence: 11
  givenname: Chenliang
  surname: Zhou
  fullname: Zhou, Chenliang
  organization: Renmin Hospital of Wuhan University
– sequence: 12
  givenname: Xiaobei
  surname: Chen
  fullname: Chen, Xiaobei
  organization: Renmin Hospital of Wuhan University
– sequence: 13
  givenname: Xiaoqin
  surname: Zheng
  fullname: Zheng, Xiaoqin
  organization: Zhejiang University
– sequence: 14
  givenname: Kaijin
  surname: Xu
  fullname: Xu, Kaijin
  organization: Zhejiang University
– sequence: 15
  givenname: Hongliu
  surname: Cai
  fullname: Cai, Hongliu
  organization: Zhejiang University
– sequence: 16
  givenname: Shufa
  surname: Zheng
  fullname: Zheng, Shufa
  organization: Zhejiang University
– sequence: 17
  givenname: Wubian
  surname: Jiang
  fullname: Jiang, Wubian
  organization: Renmin Hospital of Wuhan University
– sequence: 18
  givenname: Xiaojun
  surname: Wu
  fullname: Wu, Xiaojun
  organization: Renmin Hospital of Wuhan University
– sequence: 19
  givenname: Dong
  surname: Li
  fullname: Li, Dong
  organization: Renmin Hospital of Wuhan University
– sequence: 20
  givenname: Lu
  surname: Chen
  fullname: Chen, Lu
  organization: Innovative Precision Medicine (IPM) Group
– sequence: 21
  givenname: Qingqing
  surname: Luo
  fullname: Luo, Qingqing
  organization: Innovative Precision Medicine (IPM) Group
– sequence: 22
  givenname: Yingyan
  surname: Wang
  fullname: Wang, Yingyan
  organization: Innovative Precision Medicine (IPM) Group
– sequence: 23
  givenname: Jingjing
  surname: Qu
  fullname: Qu, Jingjing
  organization: Zhejiang University
– sequence: 24
  givenname: Yifei
  surname: Li
  fullname: Li, Yifei
  organization: Zhejiang University
– sequence: 25
  givenname: Wendi
  surname: Zheng
  fullname: Zheng, Wendi
  organization: Zhejiang University
– sequence: 26
  givenname: Yingan
  surname: Jiang
  fullname: Jiang, Yingan
  email: jiangya_cn@aliyun.com
  organization: Renmin Hospital of Wuhan University
– sequence: 27
  givenname: Lingling
  surname: Tang
  fullname: Tang, Lingling
  email: lltang72@126.com
  organization: Shulan (Hangzhou) Hospital, Zhejiang Shuren University Shulan International Medical College
– sequence: 28
  givenname: Charlie
  orcidid: 0000-0002-9193-3900
  surname: Xiang
  fullname: Xiang, Charlie
  email: cxiang@zju.edu.cn
  organization: Zhejiang University
– sequence: 29
  givenname: Lanjuan
  surname: Li
  fullname: Li, Lanjuan
  email: ljli@zju.edu.cn
  organization: Shulan (Hangzhou) Hospital, Zhejiang Shuren University Shulan International Medical College
BackLink https://www.ncbi.nlm.nih.gov/pubmed/33634996$$D View this record in MEDLINE/PubMed
BookMark eNp9ksFu1DAQQCNUREupxBcgS1x62eI4ThxzQKqWAisV9VK4Wo492fXKsRc7WciNT-CX-BW-BGe3VFskyCEeZZ7feJx5mh057yDLnuf4IseYvFJ9Ry4IZ4-yE4JxPssLUh0dxMfZWYxrnJ6acs7Ik-y4KKoixdVJ9vNqK-0ge-Md8i3qV4CibKEfkXQaQdsaJdU4pYZo3BKthk461IGLfRikRY31Xv_6_kNDMFvQKRPBqdXYpVxC_LQqsDYi41AfIFVKlghbCLAroYLpUw1rR2SsRfObz4u3yZdztEksuD6-RpcOwbeN9UH2PoxIWeOmLclnpH2WPW6ljXB2t55mn95d3c4_zK5v3i_ml9czVfKSzSQrlVYNA84bnt6tphJDqVRDWiWJyqlmhFcKiqKgjdQSNGVcFTWlWmmGi9NssfdqL9diE0wnwyi8NGL3wYelkCG1YkGUJdaKsxqrpqEFKC4Zk9DWtcZcVmWbXG_2rs3QdKBVajNI-0D6MOPMSiz9VrC64LzkSXB-Jwj-ywCxF52J0z1LB36IglBOSfrBZEJf_oWu_RBcuipBWIXrnNI6_y9FdwyvD8qq4GMM0N4fOcdiGkYxDaNIw5jQF4ct3oN_Ri8Bsz3w1VgY_ykS89uPZBL-Bj9m8Qw
CitedBy_id crossref_primary_10_1007_s00441_024_03881_y
crossref_primary_10_1177_09636897231184611
crossref_primary_10_1186_s12967_024_05358_6
crossref_primary_10_3390_v15112148
crossref_primary_10_3389_fimmu_2023_1232472
crossref_primary_10_1186_s43556_021_00067_8
crossref_primary_10_1016_j_ebiom_2022_103920
crossref_primary_10_3389_fimmu_2021_738697
crossref_primary_10_1186_s13287_021_02551_y
crossref_primary_10_3390_antiox10060881
crossref_primary_10_1089_scd_2021_0179
crossref_primary_10_3390_cells11142175
crossref_primary_10_1089_scd_2021_0015
crossref_primary_10_1002_ctm2_680
crossref_primary_10_1186_s13054_022_04287_4
crossref_primary_10_4252_wjsc_v15_i9_876
crossref_primary_10_1007_s11033_022_07957_2
crossref_primary_10_1007_s10787_023_01394_8
crossref_primary_10_3390_ijms232314681
crossref_primary_10_3389_fimmu_2022_932360
crossref_primary_10_1055_a_1720_7975
crossref_primary_10_3390_biomedicines9111691
crossref_primary_10_1016_j_intimp_2021_107694
crossref_primary_10_1016_j_reprotox_2022_03_006
crossref_primary_10_1016_j_mtbio_2023_100877
crossref_primary_10_1186_s13287_022_03034_4
crossref_primary_10_3389_fcell_2021_725606
crossref_primary_10_3389_fcell_2023_1146835
crossref_primary_10_3390_ijms24043376
crossref_primary_10_3389_fimmu_2022_963445
crossref_primary_10_1080_07399332_2021_2004149
crossref_primary_10_2174_1574888X18666230118122256
crossref_primary_10_3389_fmed_2023_1321303
crossref_primary_10_1186_s13063_022_06220_0
crossref_primary_10_2147_BTT_S404421
crossref_primary_10_2174_1574888X16666211206145839
crossref_primary_10_3389_fcell_2023_1031331
crossref_primary_10_1007_s12325_023_02507_z
crossref_primary_10_1128_cmr_00188_21
crossref_primary_10_3389_fimmu_2024_1321236
crossref_primary_10_1186_s13287_022_02810_6
crossref_primary_10_1186_s13287_022_02812_4
crossref_primary_10_1186_s13287_023_03402_8
crossref_primary_10_2478_sjecr_2021_0024
crossref_primary_10_3389_fimmu_2023_1200180
crossref_primary_10_3390_ijms24054435
crossref_primary_10_1016_j_ebiom_2021_103789
crossref_primary_10_1186_s13287_021_02559_4
crossref_primary_10_1093_stcltm_szac032
crossref_primary_10_1186_s13287_021_02511_6
crossref_primary_10_1093_stcltm_szac038
crossref_primary_10_3390_ijms241914800
crossref_primary_10_1002_ctd2_22
crossref_primary_10_1016_j_biopha_2022_113107
crossref_primary_10_1016_j_ymthe_2023_01_025
crossref_primary_10_3390_pharmaceutics13091481
crossref_primary_10_4252_wjsc_v16_i4_353
crossref_primary_10_1007_s11033_023_09174_x
crossref_primary_10_1038_s41419_023_05597_3
crossref_primary_10_2217_imt_2021_0245
crossref_primary_10_3389_fmed_2021_737590
crossref_primary_10_1007_s00018_021_04096_y
crossref_primary_10_3389_fimmu_2022_839844
crossref_primary_10_1017_erm_2021_30
crossref_primary_10_3390_ijms24098068
crossref_primary_10_1016_j_eclinm_2022_101545
crossref_primary_10_1016_j_cytogfr_2022_07_002
crossref_primary_10_1016_j_intimp_2023_110890
crossref_primary_10_1186_s13287_022_02985_y
crossref_primary_10_1007_s12010_022_04205_y
crossref_primary_10_1186_s13287_024_03707_2
crossref_primary_10_1186_s13287_022_02743_0
crossref_primary_10_1186_s13287_022_02838_8
crossref_primary_10_1186_s13287_023_03522_1
crossref_primary_10_1155_2022_3014123
crossref_primary_10_26685_urncst_319
crossref_primary_10_1177_09636897221086971
crossref_primary_10_1016_j_phrs_2022_106304
crossref_primary_10_1038_s41409_024_02230_5
Cites_doi 10.1056/NEJMoa2026920
10.1155/2019/4236973
10.1016/j.stem.2018.05.004
10.3389/fbioe.2020.00554
10.1016/S2213-2600(14)70291-7
10.1038/s41392-020-00286-5
10.1038/s41536-020-00105-z
10.1016/S0140-6736(20)30183-5
10.1016/S0140-6736(20)32661-1
10.1016/S2213-2600(20)30076-X
10.1038/s41586-020-2639-4
10.5966/sctm.2015-0265
10.1186/s13287-019-1503-7
10.1089/scd.2013.0390
10.1007/s11684-020-0757-x
10.1038/s41565-020-0732-3
10.1016/S0140-6736(20)31208-3
10.1172/JCI137244
10.1002/sctm.20-0197
10.14336/AD.2020.0228
10.1038/nri2395
10.1016/j.cell.2020.08.021
10.1038/s41422-020-0282-0
10.1016/8756-3282(92)90364-3
10.1126/science.abb4557
10.1016/j.molmed.2018.12.006
10.1002/sctm.19-0044
10.1001/jama.2020.12839
10.1038/nri3209
10.1186/s13287-018-1105-9
10.1056/NEJMoa2002032
10.1186/s13287-020-01802-8
10.1038/d41573-020-00016-0
10.1016/j.chest.2020.10.054
10.1002/ctm2.158
10.1016/S0140-6736(20)31022-9
10.1056/NEJMoa2022483
10.1093/cid/ciaa247
10.1016/j.cell.2020.07.024
10.1016/S0140-6736(20)32228-5
10.1016/S0140-6736(20)30211-7
10.1371/journal.pone.0042182
10.1002/ctm2.7
10.1016/j.jaut.2020.102433
10.2349/biij.4.1.e5
10.1038/s41586-020-2381-y
10.1016/j.jcyt.2019.08.002
10.1016/j.phrs.2020.104761
10.1002/sctm.20-0146
10.1016/S0140-6736(20)30154-9
10.3389/fimmu.2020.00243
10.1002/ctm2.44
10.1016/j.stemcr.2020.09.003
10.1038/s41586-020-2607-z
10.1186/s13287-020-01875-5
10.1186/s13287-020-01855-9
10.1038/s41591-020-1036-8
10.1002/sctm.20-0083
10.1016/S0140-6736(20)31604-4
10.1007/s11684-020-0810-9
10.1002/stem.3016
10.1007/978-3-319-45457-3_7
10.1038/s41422-020-00444-y
10.1016/j.cell.2020.05.041
10.1056/NEJMoa2007764
10.1056/NEJMoa2021436
10.3389/fimmu.2014.00205
10.1136/bmj.m2516
10.1016/j.cell.2020.04.045
10.1016/j.cell.2020.02.058
10.1186/s13287-020-01926-x
10.1186/s13287-020-01866-6
10.1073/pnas.2004168117
10.1126/science.abb4218
10.1016/j.jinf.2004.09.008
10.1016/S0140-6736(20)30185-9
10.1002/sctm.20-0164
10.1136/bmj.m606
10.1016/S0140-6736(20)32466-1
10.1038/s41591-020-1051-9
10.3727/096368915X689622
10.1016/S1473-3099(20)30843-4
10.1002/sctm.20-0245
10.1016/j.stem.2012.05.015
10.1016/S1473-3099(20)30831-8
10.1016/j.jcyt.2018.01.009
10.1186/s13287-019-1243-8
10.1038/s41586-020-2196-x
10.1016/j.it.2020.11.003
10.1146/annurev-cellbio-100913-013132
10.7150/thno.47987
10.1016/S1473-3099(20)30243-7
10.3389/fimmu.2019.01645
10.1186/s12967-020-02532-4
10.1038/s41467-020-18319-6
10.1093/cid/ciaa322
10.3389/fimmu.2020.01091
10.1186/1465-9921-15-39
ContentType Journal Article
Web Resource
Copyright 2021 The Authors. published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics
2021 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.
2021. This work is published under http://creativecommons.org/licenses/by/4.0 (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
Copyright_xml – notice: 2021 The Authors. published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics
– notice: 2021 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.
– notice: 2021. This work is published under http://creativecommons.org/licenses/by/4.0 (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
– notice: 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.
DBID 24P
WIN
CGR
CUY
CVF
ECM
EIF
NPM
AAYXX
CITATION
COVID
3V.
7X7
7XB
8AO
8FI
8FJ
8FK
ABUWG
AFKRA
AN0
AZQEC
BENPR
CCPQU
DWQXO
FYUFA
GHDGH
K9.
M0S
PIMPY
PQEST
PQQKQ
PQUKI
PRINS
7X8
5PM
DOA
DOI 10.1002/ctm2.297
DatabaseName Wiley Online Library Open Access
Wiley Online Library Journals
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
CrossRef
Coronavirus Research Database
ProQuest Central (Corporate)
ProQuest Health & Medical Collection
ProQuest Central (purchase pre-March 2016)
ProQuest Pharma Collection
Hospital Premium Collection
Hospital Premium Collection (Alumni Edition)
ProQuest Central (Alumni) (purchase pre-March 2016)
ProQuest Central (Alumni)
ProQuest Central UK/Ireland
British Nursing Database
ProQuest Central Essentials
ProQuest Central
ProQuest One Community College
ProQuest Central Korea
Health Research Premium Collection
Health Research Premium Collection (Alumni)
ProQuest Health & Medical Complete (Alumni)
Health & Medical Collection (Alumni Edition)
Publicly Available Content Database
ProQuest One Academic Eastern Edition (DO NOT USE)
ProQuest One Academic
ProQuest One Academic UKI Edition
ProQuest Central China
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
CrossRef
Coronavirus Research Database
Publicly Available Content Database
ProQuest Central Essentials
ProQuest One Academic Eastern Edition
ProQuest Health & Medical Complete (Alumni)
British Nursing Index with Full Text
ProQuest Central (Alumni Edition)
ProQuest One Community College
ProQuest Hospital Collection
Health Research Premium Collection (Alumni)
ProQuest Pharma Collection
ProQuest Central China
ProQuest Hospital Collection (Alumni)
ProQuest Central
ProQuest Health & Medical Complete
Health Research Premium Collection
ProQuest One Academic UKI Edition
Health and Medicine Complete (Alumni Edition)
ProQuest Central Korea
ProQuest One Academic
ProQuest Central (Alumni)
MEDLINE - Academic
DatabaseTitleList Coronavirus Research Database
MEDLINE - Academic
CrossRef

Publicly Available Content Database


MEDLINE
Database_xml – sequence: 1
  dbid: DOA
  name: DOAJ Directory of Open Access Journals
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: 24P
  name: Wiley Online Library Open Access
  url: https://authorservices.wiley.com/open-science/open-access/browse-journals.html
  sourceTypes: Publisher
– sequence: 3
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 4
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
– sequence: 5
  dbid: 7X7
  name: Health & Medical Collection
  url: https://search.proquest.com/healthcomplete
  sourceTypes: Aggregation Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
DocumentTitleAlternate XU et al
EISSN 2001-1326
EndPage n/a
ExternalDocumentID oai_doaj_org_article_550dc9780cbb43ec9a77aef88d09a65f
10_1002_ctm2_297
33634996
CTM2297
Genre article
Multicenter Study
Clinical Trial
Research Support, Non-U.S. Gov't
Journal Article
GeographicLocations China
GeographicLocations_xml – name: China
GrantInformation_xml – fundername: National Science & Technology Major Project “Key New Drug Creation and Manufacturing Program”
  funderid: 2018ZX09201002‐005
– fundername: the National Science and Technology Major Project
  funderid: 2017ZX10204401
– fundername: National Key R&D Program of China
  funderid: 2017YFA0105701
– fundername: National Natural Science Foundation of China
  funderid: 81900563; 81802278
– fundername: the Independent Task of State Key Laboratory for Diagnosis and Treatment of Infectious Diseases
– fundername: the Zhejiang Key Research and Development Program
  funderid: 2020C03125; 2020C04016
– fundername: National Key R&D Program of China
  grantid: 2017YFA0105701
– fundername: National Natural Science Foundation of China
  grantid: 81802278
– fundername: National Natural Science Foundation of China
  grantid: 81900563
– fundername: the National Science and Technology Major Project
  grantid: 2017ZX10204401
– fundername: National Science & Technology Major Project "Key New Drug Creation and Manufacturing Program"
  grantid: 2018ZX09201002-005
– fundername: the Zhejiang Key Research and Development Program
  grantid: 2020C04016
– fundername: the Zhejiang Key Research and Development Program
  grantid: 2020C03125
– fundername: the Zhejiang Key Research and Development Program
  grantid: 2020C03125; 2020C04016
– fundername: ;
  grantid: 81900563; 81802278
– fundername: National Science & Technology Major Project “Key New Drug Creation and Manufacturing Program”
  grantid: 2018ZX09201002‐005
GroupedDBID -A0
0R~
1OC
24P
2VQ
3V.
4.4
53G
5VS
7X7
8AO
8FI
8FJ
AAHHS
AAKKN
AAYZJ
ABDBF
ABEEZ
ABUWG
ACACY
ACCFJ
ACGFS
ACULB
ACXQS
ADBBV
ADINQ
ADRAZ
ADZOD
AEEZP
AEQDE
AFGXO
AFKRA
AHBXF
AHBYD
AHMBA
AHSBF
AHYZX
AIWBW
AJBDE
ALIPV
ALMA_UNASSIGNED_HOLDINGS
ALUQN
AMKLP
AMTXH
AN0
AOIJS
BAPOH
BAWUL
BCNDV
BENPR
BFQNJ
BNQBC
BPHCQ
BVXVI
C24
C6C
CCPQU
DIK
EBS
EJD
FYUFA
GROUPED_DOAJ
GX1
H13
HMCUK
HYE
IAO
KQ8
M48
M~E
OK1
PIMPY
PQQKQ
PROAC
RBZ
RNS
RPM
RSV
SMD
SOJ
UKHRP
WIN
CGR
CUY
CVF
ECM
EIF
ITC
NPM
AAYXX
CITATION
COVID
7XB
8FK
AZQEC
DWQXO
K9.
PQEST
PQUKI
PRINS
7X8
5PM
ID FETCH-LOGICAL-c5957-a75cdcb7e99b97e9fd4a0e5ccb2fca2c14d7296ce3334badaed479c3844dcd703
IEDL.DBID RPM
ISSN 2001-1326
IngestDate Fri Oct 04 13:12:27 EDT 2024
Tue Sep 17 21:08:49 EDT 2024
Tue Aug 06 16:31:11 EDT 2024
Thu Oct 10 20:17:43 EDT 2024
Thu Oct 10 19:09:23 EDT 2024
Thu Sep 26 16:29:57 EDT 2024
Fri Oct 18 09:10:31 EDT 2024
Sat Aug 24 01:02:58 EDT 2024
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue 2
Keywords safety and efficacy
severe and critical patients
coronavirus disease 2019 (COVID-19)
mesenchymal stromal cells
Language English
License Attribution
2021 The Authors. Clinical and Translational Medicine published by John Wiley & Sons Australia, Ltd on behalf of Shanghai Institute of Clinical Bioinformatics.
This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c5957-a75cdcb7e99b97e9fd4a0e5ccb2fca2c14d7296ce3334badaed479c3844dcd703
Notes Xiaowei Xu, Wanli Jiang, Lijun Chen, and Zhenyu Xu contributed equally to this manuscript.
ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
content type line 23
ORCID 0000-0001-9374-6466
0000-0003-1007-3951
0000-0002-9193-3900
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7839959/
PMID 33634996
PQID 2481448989
PQPubID 4686273
PageCount 22
ParticipantIDs doaj_primary_oai_doaj_org_article_550dc9780cbb43ec9a77aef88d09a65f
pubmedcentral_primary_oai_pubmedcentral_nih_gov_7839959
proquest_miscellaneous_2494299629
proquest_journals_2760814481
proquest_journals_2481448989
crossref_primary_10_1002_ctm2_297
pubmed_primary_33634996
wiley_primary_10_1002_ctm2_297_CTM2297
PublicationCentury 2000
PublicationDate February 2021
PublicationDateYYYYMMDD 2021-02-01
PublicationDate_xml – month: 02
  year: 2021
  text: February 2021
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Hoboken
– name: Heidelberg
PublicationTitle Clinical and Translational Medicine
PublicationTitleAlternate Clin Transl Med
PublicationYear 2021
Publisher John Wiley & Sons, Inc
John Wiley and Sons Inc
Wiley
Publisher_xml – name: John Wiley & Sons, Inc
– name: John Wiley and Sons Inc
– name: Wiley
References 2017; 6
2019; 2019
2021; 21
2020; 20
2019; 10
2020; 324
2020; 368
2020; 15
2008; 8
2020; 14
1992; 13
2020; 11
2020; 10
2008; 4
2012; 12
2012; 10
2014; 23
2020; 19
2020; 18
2020; 8
2020; 6
2020; 5
2014; 5
2021; 31
2020; 130
2019; 21
2020; 370
2019; 25
2020; 9
2014; 15
2021; 397
2016; 951
2021; 396
2019; 8
2021; 42
2015; 3
2020; 581
2020; 383
2020; 382
2020; 181
2020; 182
2019; 37
2020; 584
2020; 586
2018; 22
2018; 20
2020; 109
2021; 10
2020; 30
2020; 396
2020; 395
2020
2020; 71
2005; 51
2020; 26
2020; 117
2020; 25
2020; 397
2014; 30
2012; 7
2016; 25
e_1_2_11_70_1
e_1_2_11_93_1
e_1_2_11_32_1
e_1_2_11_55_1
e_1_2_11_78_1
e_1_2_11_36_1
e_1_2_11_51_1
e_1_2_11_74_1
e_1_2_11_13_1
e_1_2_11_29_1
e_1_2_11_4_1
e_1_2_11_48_1
e_1_2_11_81_1
e_1_2_11_20_1
e_1_2_11_66_1
e_1_2_11_47_1
e_1_2_11_89_1
e_1_2_11_24_1
e_1_2_11_62_1
e_1_2_11_8_1
e_1_2_11_43_1
e_1_2_11_85_1
e_1_2_11_17_1
e_1_2_11_59_1
e_1_2_11_50_1
e_1_2_11_92_1
e_1_2_11_31_1
e_1_2_11_77_1
e_1_2_11_58_1
e_1_2_11_35_1
e_1_2_11_73_1
e_1_2_11_12_1
e_1_2_11_54_1
e_1_2_11_96_1
e_1_2_11_28_1
e_1_2_11_5_1
Sánchez‐Guijo F (e_1_2_11_97_1) 2020; 25
e_1_2_11_61_1
e_1_2_11_80_1
e_1_2_11_46_1
e_1_2_11_69_1
e_1_2_11_88_1
e_1_2_11_9_1
e_1_2_11_23_1
e_1_2_11_42_1
e_1_2_11_65_1
e_1_2_11_84_1
e_1_2_11_16_1
e_1_2_11_39_1
e_1_2_11_72_1
e_1_2_11_91_1
e_1_2_11_30_1
e_1_2_11_57_1
e_1_2_11_99_1
e_1_2_11_34_1
e_1_2_11_53_1
e_1_2_11_76_1
e_1_2_11_95_1
e_1_2_11_11_1
e_1_2_11_6_1
e_1_2_11_27_1
e_1_2_11_2_1
e_1_2_11_100_1
e_1_2_11_83_1
e_1_2_11_60_1
e_1_2_11_45_1
e_1_2_11_68_1
e_1_2_11_41_1
e_1_2_11_87_1
e_1_2_11_22_1
e_1_2_11_64_1
e_1_2_11_15_1
e_1_2_11_38_1
e_1_2_11_19_1
e_1_2_11_94_1
e_1_2_11_71_1
e_1_2_11_90_1
e_1_2_11_10_1
e_1_2_11_79_1
e_1_2_11_14_1
e_1_2_11_52_1
e_1_2_11_98_1
e_1_2_11_33_1
e_1_2_11_75_1
e_1_2_11_7_1
e_1_2_11_26_1
e_1_2_11_3_1
e_1_2_11_49_1
e_1_2_11_101_1
Chen J (e_1_2_11_56_1) 2020; 6
e_1_2_11_82_1
e_1_2_11_21_1
e_1_2_11_44_1
e_1_2_11_67_1
e_1_2_11_25_1
e_1_2_11_40_1
e_1_2_11_63_1
e_1_2_11_86_1
e_1_2_11_18_1
e_1_2_11_37_1
References_xml – volume: 20
  start-page: 669
  issue: 6
  year: 2020
  end-page: 677
  article-title: Estimates of the severity of coronavirus disease 2019: a model‐based analysis
  publication-title: Lancet Infect Diseases
– volume: 11
  start-page: 477
  issue: 1
  year: 2020
  article-title: Human menstrual blood‐derived stem cells mitigate bleomycin‐induced pulmonary fibrosis through anti‐apoptosis and anti‐inflammatory effects
  publication-title: Stem Cell Res Ther
– volume: 181
  start-page: 281
  issue: 2
  year: 2020
  end-page: 292
  article-title: Structure, function, and antigenicity of the SARS‐CoV‐2 spike glycoprotein
  publication-title: Cell
– year: 2020
  article-title: Dexamethasone in hospitalized patients with Covid‐19—preliminary report
  publication-title: N Engl J Med
– volume: 4
  issue: 1
  year: 2008
  article-title: The importance of good clinical practice guidelines and its role in clinical trials
  publication-title: Biomed Imaging Interv J
– volume: 25
  start-page: 829
  issue: 5
  year: 2016
  end-page: 848
  article-title: Clinical trials with mesenchymal stem cells: an update
  publication-title: Cell Transplant
– volume: 8
  start-page: 554
  year: 2020
  article-title: Can stem cells beat COVID‐19: advancing stem cells and extracellular vesicles toward mainstream medicine for lung injuries associated with SARS‐CoV‐2 infections
  publication-title: Front Bioeng Biotechnol
– volume: 395
  start-page: 470
  issue: 10223
  year: 2020
  end-page: 473
  article-title: A novel coronavirus outbreak of global health concern
  publication-title: Lancet
– volume: 395
  start-page: 514
  issue: 10223
  year: 2020
  end-page: 523
  article-title: A familial cluster of pneumonia associated with the 2019 novel coronavirus indicating person‐to‐person transmission: a study of a family cluster
  publication-title: Lancet
– volume: 182
  start-page: 1271
  issue: 5
  year: 2020
  end-page: 1283
  article-title: A thermostable mRNA vaccine against COVID‐19
  publication-title: Cell
– volume: 182
  start-page: 1077
  issue: 5
  year: 2020
  end-page: 1092
  article-title: Emerging pandemic diseases: how we got to COVID‐19
  publication-title: Cell
– volume: 10
  start-page: 151
  issue: 1
  year: 2019
  article-title: Genome‐wide DNA methylation and hydroxymethylation analysis reveal human menstrual blood‐derived stem cells inhibit hepatocellular carcinoma growth through oncogenic pathway suppression via regulating 5‐hmC in enhancer elements
  publication-title: Stem Cell Res Ther
– volume: 21
  start-page: 1019
  issue: 10
  year: 2019
  end-page: 1024
  article-title: Mesenchymal stem versus stromal cells: International Society for Cell & Gene Therapy (ISCT(R)) Mesenchymal Stromal Cell committee position statement on nomenclature
  publication-title: Cytotherapy
– volume: 12
  start-page: 383
  issue: 5
  year: 2012
  end-page: 396
  article-title: Multipotent mesenchymal stromal cells and the innate immune system
  publication-title: Nat Rev Immunol
– volume: 9
  start-page: 813
  issue: 7
  year: 2020
  end-page: 814
  article-title: Mesenchymal stem cells as a potential treatment for critically ill patients with coronavirus disease 2019
  publication-title: Stem Cells Transl Med
– volume: 586
  start-page: 583
  issue: 7830
  year: 2020
  end-page: 588
  article-title: Single‐shot Ad26 vaccine protects against SARS‐CoV‐2 in rhesus macaques
  publication-title: Nature
– volume: 10
  issue: 2
  year: 2020
  article-title: COVID‐19 critical illness pathophysiology driven by diffuse pulmonary thrombi and pulmonary endothelial dysfunction responsive to thrombolysis
  publication-title: Clin Transl Med
– volume: 10
  start-page: 7821
  issue: 17
  year: 2020
  end-page: 7835
  article-title: COVID‐19: progress in diagnostics, therapy and vaccination
  publication-title: Theranostics
– volume: 9
  start-page: 1287
  issue: 11
  year: 2020
  end-page: 1302
  article-title: The rationale of using mesenchymal stem cells in patients with COVID‐19‐related acute respiratory distress syndrome: what to expect
  publication-title: Stem Cells Transl Med
– volume: 8
  start-page: 420
  issue: 4
  year: 2020
  end-page: 422
  article-title: Pathological findings of COVID‐19 associated with acute respiratory distress syndrome
  publication-title: Lancet Respir Med
– volume: 10
  start-page: 1645
  year: 2019
  article-title: Mesenchymal stromal cell therapeutic delivery: translational challenges to clinical application
  publication-title: Front Immunol
– volume: 10
  start-page: 709
  issue: 6
  year: 2012
  end-page: 716
  article-title: Mesenchymal stromal cells: new directions
  publication-title: Cell Stem Cell
– volume: 368
  start-page: 493
  issue: 6490
  year: 2020
  end-page: 497
  article-title: The effect of human mobility and control measures on the COVID‐19 epidemic in China
  publication-title: Science (New York, NY)
– volume: 11
  start-page: 291
  issue: 1
  year: 2020
  article-title: A synergistic role of convalescent plasma and mesenchymal stem cells in the treatment of severely ill COVID‐19 patients: a clinical case report
  publication-title: Stem Cell Res Ther
– volume: 586
  start-page: 589
  issue: 7830
  year: 2020
  end-page: 593
  article-title: Phase I/II study of COVID‐19 RNA vaccine BNT162b1 in adults
  publication-title: Nature
– volume: 10
  start-page: 27
  issue: 1
  year: 2021
  end-page: 38
  article-title: Coronavirus disease 2019: a tissue engineering and regenerative medicine perspective
  publication-title: Stem Cells Transl Med
– volume: 324
  start-page: 782
  issue: 8
  year: 2020
  end-page: 793
  article-title: Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID‐19): a review
  publication-title: JAMA
– volume: 368
  start-page: m606
  year: 2020
  article-title: Clinical findings in a group of patients infected with the 2019 novel coronavirus (SARS‐Cov‐2) outside of Wuhan, China: retrospective case series
  publication-title: BMJ
– volume: 31
  start-page: 25
  issue: 1
  year: 2021
  end-page: 36
  article-title: Rational development of a human antibody cocktail that deploys multiple functions to confer Pan‐SARS‐CoVs protection
  publication-title: Cell Res
– volume: 5
  start-page: 17
  issue: 1
  year: 2020
  article-title: Insights into the use of mesenchymal stem cells in COVID‐19 mediated acute respiratory failure
  publication-title: NPJ Regener Med
– volume: 15
  start-page: 39
  year: 2014
  article-title: Treatment of acute respiratory distress syndrome with allogeneic adipose‐derived mesenchymal stem cells: a randomized, placebo‐controlled pilot study
  publication-title: Respir Res
– volume: 30
  start-page: 677
  year: 2014
  end-page: 704
  article-title: Mesenchymal stem cells
  publication-title: Ann Rev Cell Develop Biol
– volume: 26
  start-page: 1636
  issue: 10
  year: 2020
  end-page: 1643
  article-title: An inflammatory cytokine signature predicts COVID‐19 severity and survival
  publication-title: Nat Med
– volume: 18
  start-page: 359
  issue: 1
  year: 2020
  article-title: The use of mesenchymal stromal cells in the treatment of coronavirus disease 2019
  publication-title: J Translatnl Med
– volume: 20
  start-page: 273
  issue: 3
  year: 2018
  end-page: 278
  article-title: MSCs—cells with many sides
  publication-title: Cytotherapy
– volume: 10
  start-page: 406
  issue: 1
  year: 2019
  article-title: Menstrual blood‐derived stem cells: toward therapeutic mechanisms, novel strategies, and future perspectives in the treatment of diseases
  publication-title: Stem Cell Res Ther
– volume: 42
  start-page: 31
  issue: 1
  year: 2021
  end-page: 44
  article-title: Combining antivirals and immunomodulators to fight COVID‐19
  publication-title: Trends Immunol
– volume: 397
  start-page: 61
  issue: 10268
  year: 2021
  end-page: 67
  article-title: Fragmented health systems in COVID‐19: rectifying the misalignment between global health security and universal health coverage
  publication-title: Lancet
– volume: 25
  start-page: 149
  issue: 2
  year: 2019
  end-page: 163
  article-title: Intravascular mesenchymal stromal/stem cell therapy product diversification: time for new clinical guidelines
  publication-title: Trends Mol Med
– volume: 581
  start-page: 465
  issue: 7809
  year: 2020
  end-page: 469
  article-title: Virological assessment of hospitalized patients with COVID‐2019
  publication-title: Nature
– volume: 23
  start-page: 1245
  issue: 11
  year: 2014
  end-page: 1257
  article-title: Transplantation of human menstrual blood progenitor cells improves hyperglycemia by promoting endogenous progenitor differentiation in type 1 diabetic mice
  publication-title: Stem Cells Dev
– volume: 8
  start-page: 1135
  issue: 11
  year: 2019
  end-page: 1148
  article-title: Challenges in clinical development of mesenchymal stromal/stem cells: concise review
  publication-title: Stem Cells Transl Med
– volume: 10
  issue: 4
  year: 2020
  article-title: COVID‐19 diagnostic testing: technology perspective
  publication-title: Clin Transl Med
– volume: 71
  start-page: 756
  issue: 15
  year: 2020
  end-page: 761
  article-title: A comparative study on the clinical features of coronavirus 2019 (COVID‐19) pneumonia with other pneumonias
  publication-title: Clin Infect Dis
– volume: 370
  year: 2020
  article-title: Diagnostic accuracy of serological tests for covid‐19: systematic review and meta‐analysis
  publication-title: BMJ
– volume: 10
  start-page: 13
  issue: 1
  year: 2020
  end-page: 16
  article-title: Collaborated effort against SARS‐CoV‐2 outbreak in China
  publication-title: Clin Transl Med
– volume: 11
  issue: 1
  year: 2020
  article-title: Molecular interaction and inhibition of SARS‐CoV‐2 binding to the ACE2 receptor
  publication-title: Nat Commun
– volume: 181
  start-page: 1423
  issue: 6
  year: 2020
  end-page: 1433
  article-title: Clinically applicable AI system for accurate diagnosis, quantitative measurements, and prognosis of COVID‐19 pneumonia using computed tomography
  publication-title: Cell
– volume: 26
  start-page: 1616
  issue: 10
  year: 2020
  end-page: 1622
  article-title: Using a real‐world network to model localized COVID‐19 control strategies
  publication-title: Nat Med
– volume: 8
  start-page: 726
  issue: 9
  year: 2008
  end-page: 736
  article-title: Mesenchymal stem cells in health and disease
  publication-title: Nat Rev Immunol
– volume: 14
  start-page: 664
  issue: 5
  year: 2020
  end-page: 673
  article-title: Clinical study using mesenchymal stem cells for the treatment of patients with severe COVID‐19
  publication-title: Front Med
– volume: 11
  start-page: 243
  year: 2020
  article-title: Editorial: safety, efficacy and mechanisms of action of mesenchymal stem cell therapies
  publication-title: Front Immunol
– volume: 7
  issue: 7
  year: 2012
  article-title: Functional characterizations of RIG‐I to GCRV and viral/bacterial PAMPs in grass carp
  publication-title: PloS one
– volume: 397
  start-page: 99
  year: 2020
  end-page: 111
  article-title: Safety and efficacy of the ChAdOx1 nCoV‐19 vaccine (AZD1222) against SARS‐CoV‐2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK
  publication-title: Lancet
– volume: 383
  start-page: 1813
  issue: 19
  year: 2020
  end-page: 1826
  article-title: Remdesivir for the treatment of Covid‐19: final report
  publication-title: N Engl J Med
– volume: 181
  start-page: 1458
  issue: 7
  year: 2020
  end-page: 1463
  article-title: Pandemic preparedness: developing vaccines and therapeutic antibodies for COVID‐19
  publication-title: Cell
– volume: 11
  start-page: 361
  issue: 1
  year: 2020
  article-title: Treatment of severe COVID‐19 with human umbilical cord mesenchymal stem cells
  publication-title: Stem Cell Res Ther
– volume: 396
  start-page: 467
  issue: 10249
  year: 2020
  end-page: 478
  article-title: Safety and immunogenicity of the ChAdOx1 nCoV‐19 vaccine against SARS‐CoV‐2: a preliminary report of a phase 1/2, single‐blind, randomised controlled trial
  publication-title: Lancet (London, England)
– volume: 11
  year: 2020
  article-title: MSC Therapies for COVID‐19: importance of patient coagulopathy, thromboprophylaxis, cell product quality and mode of delivery for treatment safety and efficacy
  publication-title: Front Immunol
– volume: 51
  start-page: 98
  issue: 2
  year: 2005
  end-page: 102
  article-title: The use of corticosteroid as treatment in SARS was associated with adverse outcomes: a retrospective cohort study
  publication-title: J Infect
– volume: 10
  start-page: 5
  issue: 1
  year: 2021
  end-page: 13
  article-title: Regen med therapeutic opportunities for fighting COVID‐19
  publication-title: Stem Cells Transl Med
– volume: 9
  start-page: 1007
  issue: 9
  year: 2020
  end-page: 1022
  article-title: Cell‐based therapy to reduce mortality from COVID‐19: systematic review and meta‐analysis of human studies on acute respiratory distress syndrome
  publication-title: Stem Cells Transl Med
– volume: 117
  start-page: 9490
  issue: 17
  year: 2020
  end-page: 9496
  article-title: Effectiveness of convalescent plasma therapy in severe COVID‐19 patients
  publication-title: Proc Natl Acad Sci USA
– volume: 368
  start-page: 742
  issue: 6492
  year: 2020
  end-page: 746
  article-title: Effective containment explains subexponential growth in recent confirmed COVID‐19 cases in China
  publication-title: Science (New York, NY)
– volume: 395
  start-page: 507
  issue: 10223
  year: 2020
  end-page: 513
  article-title: Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study
  publication-title: Lancet
– volume: 383
  start-page: 2320
  issue: 24
  year: 2020
  end-page: 2332
  article-title: Phase 1‐2 trial of a SARS‐CoV‐2 recombinant spike protein nanoparticle vaccine
  publication-title: N Engl J Med
– volume: 11
  start-page: 216
  issue: 2
  year: 2020
  end-page: 228
  article-title: Transplantation of ACE2(‐) mesenchymal stem cells improves the outcome of patients with COVID‐19 pneumonia
  publication-title: Aging Dis
– volume: 10
  issue: 1
  year: 2019
  article-title: The multi‐functional roles of menstrual blood‐derived stem cells in regenerative medicine
  publication-title: Stem Cell Res Ther
– volume: 15
  start-page: 630
  issue: 8
  year: 2020
  end-page: 645
  article-title: Immune‐mediated approaches against COVID‐19
  publication-title: Nat Nanotechnol
– volume: 30
  start-page: 269
  issue: 3
  year: 2020
  end-page: 271
  article-title: Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019‐nCoV) in vitro
  publication-title: Cell Res
– volume: 37
  start-page: 855
  issue: 7
  year: 2019
  end-page: 864
  article-title: Concise review: mesenchymal stem cells: from roots to boost
  publication-title: Stem Cells
– year: 2020
  article-title: Impact of corticosteroids in coronavirus disease 2019 outcomes: systematic review and meta‐analysis
  publication-title: Chest
– year: 2020
  article-title: Human mesenchymal stromal cells are resistant to SARS‐CoV‐2 infection under steady‐state, inflammatory conditions and in the presence of SARS‐CoV‐2‐infected cells
  publication-title: Stem Cell Reports
– volume: 5
  start-page: 172
  issue: 1
  year: 2020
  article-title: Human umbilical cord‐derived mesenchymal stem cell therapy in patients with COVID‐19: a phase 1 clinical trial
  publication-title: Signal Transduct Target Ther
– volume: 21
  start-page: 39
  issue: 1
  year: 2021
  end-page: 51
  article-title: Safety and immunogenicity of an inactivated SARS‐CoV‐2 vaccine, BBIBP‐CorV: a randomised, double‐blind, placebo‐controlled, phase 1/2 trial
  publication-title: Lancet Infect Dis
– volume: 395
  start-page: 1569
  issue: 10236
  year: 2020
  end-page: 1578
  article-title: Remdesivir in adults with severe COVID‐19: a randomised, double‐blind, placebo‐controlled, multicentre trial
  publication-title: Lancet
– volume: 19
  start-page: 149
  issue: 3
  year: 2020
  end-page: 150
  article-title: Therapeutic options for the 2019 novel coronavirus (2019‐nCoV)
  publication-title: Nat Rev Drug Discov
– volume: 3
  start-page: 24
  issue: 1
  year: 2015
  end-page: 32
  article-title: Mesenchymal stem (stromal) cells for treatment of ARDS: a phase 1 clinical trial
  publication-title: Lancet Respir Med
– volume: 395
  start-page: 1845
  issue: 10240
  year: 2020
  end-page: 1854
  article-title: Safety, tolerability, and immunogenicity of a recombinant adenovirus type‐5 vectored COVID‐19 vaccine: a dose‐escalation, open‐label, non‐randomised, first‐in‐human trial
  publication-title: Lancet
– volume: 11
  start-page: 345
  issue: 1
  year: 2020
  article-title: Mesenchymal stromal cell therapies: immunomodulatory properties and clinical progress
  publication-title: Stem Cell Res Ther
– volume: 396
  start-page: 1979
  issue: 10267
  year: 2021
  end-page: 1993
  article-title: Safety and immunogenicity of ChAdOx1 nCoV‐19 vaccine administered in a prime‐boost regimen in young and old adults (COV002): a single‐blind, randomised, controlled, phase 2/3 trial
  publication-title: Lancet (London, England)
– volume: 14
  start-page: 210
  issue: 2
  year: 2020
  end-page: 214
  article-title: Combination of western medicine and Chinese traditional patent medicine in treating a family case of COVID‐19
  publication-title: Front Med
– volume: 109
  year: 2020
  article-title: The epidemiology and pathogenesis of coronavirus disease (COVID‐19) outbreak
  publication-title: J Autoimmun
– volume: 383
  start-page: 1920
  issue: 20
  year: 2020
  end-page: 1931
  article-title: An mRNA vaccine against SARS‐CoV‐2: preliminary report
  publication-title: N Engl J Med
– volume: 2019
  year: 2019
  article-title: Mesenchymal stem cell‐based therapy of inflammatory lung diseases: current understanding and future perspectives
  publication-title: Stem Cells Int
– volume: 584
  start-page: 120
  issue: 7819
  year: 2020
  end-page: 124
  article-title: A human neutralizing antibody targets the receptor‐binding site of SARS‐CoV‐2
  publication-title: Nature
– volume: 5
  start-page: 205
  year: 2014
  article-title: The promising potential of menstrual stem cells for antenatal diagnosis and cell therapy
  publication-title: Front Immunol
– volume: 951
  start-page: 77
  year: 2016
  end-page: 98
  article-title: Cryopreserved or fresh mesenchymal stromal cells: only a matter of taste or key to unleash the full clinical potential of MSC therapy?
  publication-title: Adv Exp Med Biol
– volume: 13
  start-page: 81
  issue: 1
  year: 1992
  end-page: 88
  article-title: Characterization of cells with osteogenic potential from human marrow
  publication-title: Bone
– volume: 395
  start-page: 497
  issue: 10223
  year: 2020
  end-page: 506
  article-title: Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China
  publication-title: Lancet
– year: 2020
  article-title: Safety, tolerability, and immunogenicity of an inactivated SARS‐CoV‐2 vaccine in healthy adults aged 18‐59 years: a randomised, double‐blind, placebo‐controlled, phase 1/2 clinical trial
  publication-title: Lancet Infect Dis
– volume: 6
  start-page: 1153
  issue: 10
  year: 2020
  end-page: 1161
  article-title: Clinical study of mesenchymal stem cell treating acute respiratory distress syndrome induced by epidemic Influenza A (H7N9) infection, a hint for COVID‐19 treatment
  publication-title: Engineering (Beijing)
– volume: 25
  year: 2020
  article-title: Adipose‐derived mesenchymal stromal cells for the treatment of patients with severe SARS‐CoV‐2 pneumonia requiring mechanical ventilation. A proof of concept study
  publication-title: E Clin Med
– volume: 382
  start-page: 1708
  issue: 18
  year: 2020
  end-page: 1720
  article-title: Clinical characteristics of coronavirus disease 2019 in China
  publication-title: N Engl J Med
– volume: 130
  start-page: 2620
  issue: 5
  year: 2020
  end-page: 2629
  article-title: Clinical and immunological features of severe and moderate coronavirus disease 2019
  publication-title: J Clin Invest
– volume: 6
  start-page: 272
  issue: 1
  year: 2017
  end-page: 284
  article-title: Human menstrual blood‐derived stem cells ameliorate liver fibrosis in mice by targeting hepatic stellate cells via paracrine mediators
  publication-title: Stem Cells Transl Med
– volume: 11
  start-page: 356
  issue: 1
  year: 2020
  article-title: Potential therapeutic application of mesenchymal stem cell‐derived exosomes in SARS‐CoV‐2 pneumonia
  publication-title: Stem Cell Res Ther
– year: 2020
  article-title: Lianhuaqingwen exerts anti‐viral and anti‐inflammatory activity against novel coronavirus (SARS‐CoV‐2)
  publication-title: Pharmacol Res
– volume: 71
  start-page: 786
  issue: 15
  year: 2020
  end-page: 792
  article-title: Epidemiological and clinical predictors of COVID‐19
  publication-title: Clin Infect Dis
– volume: 22
  start-page: 824
  issue: 6
  year: 2018
  end-page: 833
  article-title: Mesenchymal stromal cells: clinical challenges and therapeutic opportunities
  publication-title: Cell Stem Cell
– volume: 25
  start-page: 100454
  year: 2020
  ident: e_1_2_11_97_1
  article-title: Adipose‐derived mesenchymal stromal cells for the treatment of patients with severe SARS‐CoV‐2 pneumonia requiring mechanical ventilation. A proof of concept study
  publication-title: E Clin Med
  contributor:
    fullname: Sánchez‐Guijo F
– ident: e_1_2_11_34_1
  doi: 10.1056/NEJMoa2026920
– ident: e_1_2_11_50_1
  doi: 10.1155/2019/4236973
– ident: e_1_2_11_42_1
  doi: 10.1016/j.stem.2018.05.004
– ident: e_1_2_11_85_1
  doi: 10.3389/fbioe.2020.00554
– ident: e_1_2_11_55_1
  doi: 10.1016/S2213-2600(14)70291-7
– ident: e_1_2_11_58_1
  doi: 10.1038/s41392-020-00286-5
– ident: e_1_2_11_94_1
  doi: 10.1038/s41536-020-00105-z
– ident: e_1_2_11_2_1
  doi: 10.1016/S0140-6736(20)30183-5
– ident: e_1_2_11_28_1
  doi: 10.1016/S0140-6736(20)32661-1
– ident: e_1_2_11_15_1
  doi: 10.1016/S2213-2600(20)30076-X
– ident: e_1_2_11_27_1
  doi: 10.1038/s41586-020-2639-4
– ident: e_1_2_11_65_1
  doi: 10.5966/sctm.2015-0265
– ident: e_1_2_11_48_1
  doi: 10.1186/s13287-019-1503-7
– ident: e_1_2_11_60_1
  doi: 10.1089/scd.2013.0390
– ident: e_1_2_11_87_1
  doi: 10.1007/s11684-020-0757-x
– ident: e_1_2_11_89_1
  doi: 10.1038/s41565-020-0732-3
– ident: e_1_2_11_25_1
  doi: 10.1016/S0140-6736(20)31208-3
– ident: e_1_2_11_63_1
  doi: 10.1172/JCI137244
– ident: e_1_2_11_75_1
  doi: 10.1002/sctm.20-0197
– ident: e_1_2_11_54_1
  doi: 10.14336/AD.2020.0228
– ident: e_1_2_11_39_1
  doi: 10.1038/nri2395
– ident: e_1_2_11_5_1
  doi: 10.1016/j.cell.2020.08.021
– ident: e_1_2_11_80_1
  doi: 10.1038/s41422-020-0282-0
– ident: e_1_2_11_35_1
  doi: 10.1016/8756-3282(92)90364-3
– ident: e_1_2_11_72_1
  doi: 10.1126/science.abb4557
– ident: e_1_2_11_44_1
  doi: 10.1016/j.molmed.2018.12.006
– ident: e_1_2_11_49_1
  doi: 10.1002/sctm.19-0044
– ident: e_1_2_11_12_1
  doi: 10.1001/jama.2020.12839
– ident: e_1_2_11_40_1
  doi: 10.1038/nri3209
– ident: e_1_2_11_61_1
  doi: 10.1186/s13287-018-1105-9
– ident: e_1_2_11_3_1
  doi: 10.1056/NEJMoa2002032
– ident: e_1_2_11_98_1
  doi: 10.1186/s13287-020-01802-8
– ident: e_1_2_11_18_1
  doi: 10.1038/d41573-020-00016-0
– ident: e_1_2_11_84_1
  doi: 10.1016/j.chest.2020.10.054
– ident: e_1_2_11_14_1
  doi: 10.1002/ctm2.158
– ident: e_1_2_11_24_1
  doi: 10.1016/S0140-6736(20)31022-9
– ident: e_1_2_11_30_1
  doi: 10.1056/NEJMoa2022483
– ident: e_1_2_11_70_1
  doi: 10.1093/cid/ciaa247
– ident: e_1_2_11_78_1
  doi: 10.1016/j.cell.2020.07.024
– ident: e_1_2_11_6_1
  doi: 10.1016/S0140-6736(20)32228-5
– ident: e_1_2_11_10_1
  doi: 10.1016/S0140-6736(20)30211-7
– ident: e_1_2_11_68_1
  doi: 10.1371/journal.pone.0042182
– ident: e_1_2_11_8_1
  doi: 10.1002/ctm2.7
– ident: e_1_2_11_9_1
  doi: 10.1016/j.jaut.2020.102433
– ident: e_1_2_11_62_1
  doi: 10.2349/biij.4.1.e5
– ident: e_1_2_11_79_1
  doi: 10.1038/s41586-020-2381-y
– ident: e_1_2_11_36_1
  doi: 10.1016/j.jcyt.2019.08.002
– ident: e_1_2_11_88_1
  doi: 10.1016/j.phrs.2020.104761
– ident: e_1_2_11_93_1
  doi: 10.1002/sctm.20-0146
– ident: e_1_2_11_7_1
  doi: 10.1016/S0140-6736(20)30154-9
– ident: e_1_2_11_99_1
  doi: 10.3389/fimmu.2020.00243
– ident: e_1_2_11_19_1
  doi: 10.1002/ctm2.44
– ident: e_1_2_11_53_1
  doi: 10.1016/j.stemcr.2020.09.003
– volume: 6
  start-page: 1153
  issue: 10
  year: 2020
  ident: e_1_2_11_56_1
  article-title: Clinical study of mesenchymal stem cell treating acute respiratory distress syndrome induced by epidemic Influenza A (H7N9) infection, a hint for COVID‐19 treatment
  publication-title: Engineering (Beijing)
  contributor:
    fullname: Chen J
– ident: e_1_2_11_31_1
  doi: 10.1038/s41586-020-2607-z
– ident: e_1_2_11_96_1
  doi: 10.1186/s13287-020-01875-5
– ident: e_1_2_11_46_1
  doi: 10.1186/s13287-020-01855-9
– ident: e_1_2_11_73_1
  doi: 10.1038/s41591-020-1036-8
– ident: e_1_2_11_92_1
  doi: 10.1002/sctm.20-0083
– ident: e_1_2_11_26_1
  doi: 10.1016/S0140-6736(20)31604-4
– ident: e_1_2_11_91_1
  doi: 10.1007/s11684-020-0810-9
– ident: e_1_2_11_47_1
  doi: 10.1002/stem.3016
– ident: e_1_2_11_101_1
  doi: 10.1007/978-3-319-45457-3_7
– ident: e_1_2_11_74_1
  doi: 10.1038/s41422-020-00444-y
– ident: e_1_2_11_77_1
  doi: 10.1016/j.cell.2020.05.041
– ident: e_1_2_11_81_1
  doi: 10.1056/NEJMoa2007764
– ident: e_1_2_11_23_1
  doi: 10.1056/NEJMoa2021436
– ident: e_1_2_11_59_1
  doi: 10.3389/fimmu.2014.00205
– ident: e_1_2_11_69_1
  doi: 10.1136/bmj.m2516
– ident: e_1_2_11_76_1
  doi: 10.1016/j.cell.2020.04.045
– ident: e_1_2_11_51_1
  doi: 10.1016/j.cell.2020.02.058
– ident: e_1_2_11_67_1
  doi: 10.1186/s13287-020-01926-x
– ident: e_1_2_11_86_1
  doi: 10.1186/s13287-020-01866-6
– ident: e_1_2_11_90_1
  doi: 10.1073/pnas.2004168117
– ident: e_1_2_11_71_1
  doi: 10.1126/science.abb4218
– ident: e_1_2_11_82_1
  doi: 10.1016/j.jinf.2004.09.008
– ident: e_1_2_11_4_1
  doi: 10.1016/S0140-6736(20)30185-9
– ident: e_1_2_11_57_1
  doi: 10.1002/sctm.20-0164
– ident: e_1_2_11_13_1
  doi: 10.1136/bmj.m606
– ident: e_1_2_11_29_1
  doi: 10.1016/S0140-6736(20)32466-1
– ident: e_1_2_11_83_1
  doi: 10.1038/s41591-020-1051-9
– ident: e_1_2_11_41_1
  doi: 10.3727/096368915X689622
– ident: e_1_2_11_33_1
  doi: 10.1016/S1473-3099(20)30843-4
– ident: e_1_2_11_22_1
  doi: 10.1002/sctm.20-0245
– ident: e_1_2_11_38_1
  doi: 10.1016/j.stem.2012.05.015
– ident: e_1_2_11_32_1
  doi: 10.1016/S1473-3099(20)30831-8
– ident: e_1_2_11_45_1
  doi: 10.1016/j.jcyt.2018.01.009
– ident: e_1_2_11_66_1
  doi: 10.1186/s13287-019-1243-8
– ident: e_1_2_11_17_1
  doi: 10.1038/s41586-020-2196-x
– ident: e_1_2_11_21_1
  doi: 10.1016/j.it.2020.11.003
– ident: e_1_2_11_37_1
  doi: 10.1146/annurev-cellbio-100913-013132
– ident: e_1_2_11_20_1
  doi: 10.7150/thno.47987
– ident: e_1_2_11_64_1
  doi: 10.1016/S1473-3099(20)30243-7
– ident: e_1_2_11_43_1
  doi: 10.3389/fimmu.2019.01645
– ident: e_1_2_11_95_1
  doi: 10.1186/s12967-020-02532-4
– ident: e_1_2_11_52_1
  doi: 10.1038/s41467-020-18319-6
– ident: e_1_2_11_11_1
  doi: 10.1093/cid/ciaa322
– ident: e_1_2_11_16_1
  doi: 10.3389/fimmu.2020.01091
– ident: e_1_2_11_100_1
  doi: 10.1186/1465-9921-15-39
SSID ssj0000849972
Score 2.511587
Snippet The coronavirus disease 2019 (COVID‐19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) was identified in December 2019 and has...
The coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was identified in December 2019 and has...
Abstract The coronavirus disease 2019 (COVID‐19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) was identified in December 2019 and...
Abstract The coronavirus disease 2019 (COVID‐19), caused by severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) was identified in December 2019 and...
SourceID doaj
pubmedcentral
proquest
crossref
pubmed
wiley
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage e297
SubjectTerms Adenoviruses
Adolescent
Adult
Aged
Allografts
Clinical medicine
Clinical trials
coronavirus disease 2019 (COVID‐19)
Coronaviruses
COVID-19 - blood
COVID-19 - mortality
COVID-19 - therapy
COVID-19 vaccines
Critical Illness
Disease transmission
Disease-Free Survival
Dyspnea
Epidemics
Female
Hospitals
Humans
Infections
Male
Medical research
Menstruation
Mesenchymal Stem Cell Transplantation
Mesenchymal Stem Cells
mesenchymal stromal cells
Middle Aged
safety and efficacy
SARS-CoV-2 - metabolism
Severe acute respiratory syndrome coronavirus 2
severe and critical patients
Severity of Illness Index
Stem cells
Survival Rate
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV3NbhMxELZQD4gLovwGCjIS4rZ01z_rNbcSWhWkwKVFva38M0sjJRvEpki58Qi8Eq_CkzDj3USJKOLCaaWMNXE8n-1x9vM3jL3AFFj5JpHC8pxKmEFmcyiyqHy0Akz0jg6Kkw_l6bl6f6Evtkp9ESeslwfuB-4QM-gYSCYneK8kBOuMcdBUVcytK3WTVt9Cbx2m0hpcKboRulabzcVhWM7FK0HaTlv7T5Lpvy63_JMiuZ26pr3n5A67PSSN_Kjv7D67Ae1ddnMyvBa_x34ebzS7-aLhmNPxzjWwXHHXRg6kEuHCikxEc__MU2E-PoekHouOE3v91_cfEeH4DSJaOgTv5WqONmyyoCf9w9_xacsTNZ284J4KXyF9RRgKJsxWfDqb8fHHT-_eor_C8kG3tXvNj1oOifCX3uvz9ZVMnuqG3GfnJ8dn49NsqM2QBW21yZzRIQZvwFqPAbZNVC4HHYIXTXAiFCpi2l4GkFIq76KDqIwNslIqhojLzAO21y5aeMR47qW0smiEoHwBTyyuKp0W2E5XFqwesefriNVfegmOuhdbFjVFtcaojtgbCuXGTqLZ6QOEUj1Aqf4XlEbsYA2EepjJXS1UhWdOKrJ5vdmUeWpQYDc3ZpyiFBXXwuKKXFja9UuBLh72sNp0VMpSIlTLETM7gNv5JbuWdnqZZMBNRdeS0efLBM2_jk09PpsIfD7-H2P0hN0SxOpJvPUDtocwhaeYli39szQDfwN37T2u
  priority: 102
  providerName: Directory of Open Access Journals
– databaseName: Coronavirus Research Database
  dbid: COVID
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NbtQwELZge0EcAPG3UJCRELdsE9v5MRcES6uCVLi00Fvkn0m76m5Smi3ScuIReCVehSdhxpssXSgcOEXKWI4df7ZnnC_fMPYUXWBlq0AKi2NKYQaRjiGJvLJeC8i9NRQo7r3Ldg_U28P0sDtwaztaZb8mhoXaN47OyLeEKtD3p2SHL04_RZQ1ir6udik0rrINWWCkM2Ab4_cf3rzuVWZjseXmMzESpOl0Yd8J8vyX-ZR_UiMvuqxhz9m5wcq-tUuqycnofG5H7stvQo7_352b7PpHsLw_wL_FrkB9m33fXul_86bi6B_y1lQwX3BTew6kOGHcgkxEmT_iIckfn0FQojVTHpjwP75-8wjtz-DR0uJEOF7M0IZFGrrS14KWT2oeaO5UC-7PcAbhEa5LvjBd8Ml0ysObxvoSzTsN2PY5f1lzCOTBwBHg_e-dPOQgucMOdrb3x7tRl-chcqlO88jkqfPO5qC1RbDoyisTQ-qcFZUzwiXKYwiQOZBSKmu8Aa9y7WShlHcel6y7bFA3NdxnPLZSaplUQpDvgdGPKTKTCiyXFhp0OmRPehSUp0s5j3Ip3CxKQkqJSBmyVwSPlZ0EuMON5uyo7OZziYGdd6Te5KxVEpw2eW6gKgofa5Ol1ZBt9uNedqtCW_4a9MvNeRaHAgk2c2XG6U6jYmpozqkKTR5EJrCKe0uorhoqZSYxgM2GLF8D8VpP1i315DhIiucF_eKMdT4LcP_ruynH-3sCrw_-3b2H7Jog7k9gt2-yAQIQHqHzNrePuxn6E5KBUNg
  priority: 102
  providerName: ProQuest
– databaseName: Scholars Portal Open Access Journals
  dbid: M48
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwdV1bb9MwFLbGkKa9IO7rGMhIiLeM1HbiGAmhUTYNpMLLivYW-XKyVWoT1hZEfxz_jXPcpFpF9xQpx3Eu53P8Hfn4O4y9QQqsXBWTwtKUSphBYlLoJ0G5YATo4CwFisNv-flIfb3MLndYV22z_YDzraEd1ZMazSbHf26WH3HAf2gFRN_5xVQcC6PvsftCSUU4H7YkP_6PC0W7Q6nKHOUPYfiVdyq0ty7eZ3tS5hKb5htTVFTy30Y__8-ivM1u4_R09pA9aHklP1kB4RHbgfox2xu2K-dP2N_Ttaw3byqOtI_PbQWLJbd14EBCEtYvyUSZ8Fc81u7jU4gCs9jxKsE9IF5_Q8Dzc0T39XKKFmzQ0JGWAOZ8XPOYu0594KQLM4g38G1FhcmSjycTPvj-48vnpG94K-s6f89Pag4xHzAu-_NuxyaPZUWestHZ6cXgPGlLNyQ-M5lOrM588E6DMQ79b6qgbAqZ905U3grfVwFZfe5BSqmcDRaC0sbLQqngA_6FnrHduqnhgPHUSWlkvxKC6AQGNLbIbSawXVYYMFmPve68Vf5cKXSUKy1mUZJzS3Ruj30iN67tpKkdTzSzq7IdoiXGasGTIJN3TknwxmptoSqKkBqbZ1WPHXUgKDuclkIVGJJSDc7tZp2nsUEfH3NtxhFMPrE1NL-oC0OkIBfYxfMVpNYP2kGyx_QG2DbeZNNSj6-jSrguaNcy9vk2wvLOb1MOLoYCj4d33vwF2xeUyRNz1Y_YLuIOXiIVW7hXcaT9A-3NM_U
  priority: 102
  providerName: Scholars Portal
– databaseName: Wiley Online Library Open Access
  dbid: 24P
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwjV3NbtQwELagSIgL4p-FgoyEuIVmbSeOuZWlVUFa4NCi3iL_TNqVdhPULEh74xF4JV6FJ2HG-YEVReIUaceZTTIz8TfO-BvGniMEVq6KRWFpSi3MIDEpTJOgXDACdHCWEsX5-_zoRL07zU77qkraC9PxQ4wLbhQZ8X1NAW5du_ebNNSvV-KlMPoqu4aopiCPFurjuL6SFor2hFJvOaoawqQrH7hnU7E3nLw1G0XS_suQ5t8Fk38C2TgTHd5iN3sIyfc7m99mV6C-w67P-4_kd9mPg5HBmzcVR4THW1vBesNtHTgQZ4T1GxJR0fsZj236-AoilywqjrXsP799D-icXyGgpEVXPt-sUIZDGjrSen_LFzWPheqkBWdYuID4F75vn7Dc8MVyyWcfPr19g_qmhvcsru0rvl9ziOV_8Ss_HzZo8thF5B47OTw4nh0lfaeGxGcm04nVmQ_eaTDGoblNFZRNIfPeicpb4acqIIjPPUgplbPBQlDaeFkoFXzAl859tlM3NTxkPHVSGjmthCD0gPmLLXKbCRyHNgaTTdizwWLl546Qo-yol0VJVi3RqhP2mkw5yolCO_7QXJyVfUSWmJoFT_xL3jklwRurtYWqKEJqbJ5VE7Y7OELZx3VbClVgBkotNy8X6zyNA6Z4maMYA5asYmtovpAKQxggF6jiQedW44VKmUt023zC9JbDbd3JtqRenEdScF3QJmXU-SK65j-fTTk7ngs8PvrfgY_ZDUF1PLFSfZftoCvCEwRia_c0RtwvJa41mA
  priority: 102
  providerName: Wiley-Blackwell
Title Evaluation of the safety and efficacy of using human menstrual blood‐derived mesenchymal stromal cells in treating severe and critically ill COVID‐19 patients: An exploratory clinical trial
URI https://onlinelibrary.wiley.com/doi/abs/10.1002%2Fctm2.297
https://www.ncbi.nlm.nih.gov/pubmed/33634996
https://www.proquest.com/docview/2481448989
https://www.proquest.com/docview/2760814481
https://www.proquest.com/docview/2494299629/abstract/
https://pubmed.ncbi.nlm.nih.gov/PMC7839959
https://doaj.org/article/550dc9780cbb43ec9a77aef88d09a65f
Volume 11
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NbtNAEF41RUJcEP81lGiRELckzu7a6-XWhlQFySVCLcrN2j-3kWKnagJSbjwCr8Sr8CTMTuyoEeXCxSt5Vuu1Z8Y7Y3_7DSFvIQQWpkRQWByHEma-p2I_7DlhnGJeOqNDopifpacX4tM0me6RpN0Lg6B9a2b9el7169kVYiuvKztocWKDST6SWdiQqQYd0pGc30rR8fWbibAZtCWajdnArirWZyrU2-M85SBOd1YhJOu_K8L8Gyh5O4DFFejkEXnYhI70aDPFx2TP10_I_bz5Of6U_BpvmbvpoqQQ2dGlLv1qTXXtqA9cEdqugyiA3S8pluejlUcOWRgYMey_f_x0YJTfvQPJEkz4al2BDLosQhu-8y_prKYIUA-jwMrqbzxewjZlE-ZrOpvP6ejz148fYLyhog176_I9PaqpR9gf_t2n7cZMitVDnpGLk_H56LTXVGjo2UQlsqdlYp010itlQM2qdELHPrHWsNJqZofCQfCeWs85F0Y77Z2QyvJMCGcdvGyek_16UfsDQmPDueLDkrEQNUDeorNUJwz6JZnyKonIm1ZjxfWGiKPYUC6zIii4AAVH5DiocisP1Nl4YnFzWTQGVEBK5mzgXbLGCO6t0lJqX2aZi5VOkzIih60hFI0_LwsmMsg8Q6nNu8UyjbHDEKa5FYOjBq3o2i--hSFUWPtTBkO82JjVdqKtWUZE7hjczp3sSsA3kAy88YWIvEPT_OezKUbnOYP25X9f4hV5wAKgByHrh2QfbNO_hohsZbqkw8QEjnIqu-Te8fhs8gVaNLMufuWAYy6yLnrqH-BiRBs
link.rule.ids 230,315,733,786,790,870,891,2115,2236,11589,12083,21416,24346,27955,27956,31752,31753,33777,33778,38549,43343,43838,43928,46085,46509,53825,53827,74100,74657,74767
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LbhMxFLUgXYBYAOIVKGAkxG7Sie15mA2C0CqFpmxS6M7ya9qIZKZ0UqSw4hP4JX6FL-FeZyY0UFiwGmmu5bHHx_a9njPnEvIUXGBhikAKi2NMYeYjGft-5IRxkvnMGY2B4mg_HR6IN4fJYXPgVje0ynZNDAu1qyyekW8xkYPvj8kOX5x8ijBrFH5dbVJoXCYbsLGyvEM2Bu_e775uVWZjtmXnM9ZjqOl0bt8J8vwX-ZR_UiPPu6xhz9m5TlTb2iXV5GPvbG569stvQo7_350b5NoHb2h7gH-TXPLlLfJ9e6X_TauCgn9Ia134-YLq0lGPihPaLtCElPkjGpL80ZkPSrR6SgMT_sfXbw6g_dk7sNQwEY4XM7BBkQqv-LWgppOSBpo71gL7sz_14RG2Sb4wXdDJdErDm4b6-pI2GrD1c_qypD6QBwNHgLa_d9KQg-Q2OdjZHg-GUZPnIbKJTLJIZ4l11mReSgNgkYUTOvaJtYYVVjPbFw5CgNR6zrkw2mnvRCYtz4Vw1sGSdYd0yqr09wiNDeeS9wvG0PeA6EfnqU4YlEty6WXSJU9aFKiTpZyHWgo3M4VIUYCULnmF8FjZUYA73KhOj1QznxUEds6iepM1RnBvpc4y7Ys8d7HUaVJ0yWY77qpZFWr1a9AvNmdpHAr0oZkrM0x3HBVd-uoMq5DoQaQMqri7hOqqoZynHALYtEuyNRCv9WTdUk6Og6R4luMvzlDnswD3v74bNRiPGFzv_7t7j8mV4Xi0p_Z2998-IFcZ8oAC032TdACM_iE4cnPzqJmtPwFxdVO_
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwfV3db9MwELdgSBMviO-VDTAS4i00tZ045gWNbtUGdPCwob5F_spWqU22pSD1j-N_4851o1UMniLloouTu7PP9s-_I-QtpMDCVAEUlqZYwswnKvWDxAnjFPPSGY0TxfFJfnQmPk-yScQ_tRFWue4TQ0ftGotr5H0mcxi9YDIx6FcRFvH9YPTx8irBClK40xrLadwl92CUTLGMg5zIbr0lLQSeEV3zz6asbxdz9p4h29ONESkQ99-Wbf4NmryZzIbRaPSQPIhpJN1f2f0RuePrx2R7HDfKn5Dfhx2LN20qClkebXXlF0uqa0c98kZou0QRAt_PaSjVR-c-8MmC4hWe3YF7_vIO7rfgzBfLOUjggQavuOLf0mlNA1QddcAY6699eIGNBRRmSzqdzejw24_jg2SgaGRxbT_Q_Zr6AP8Lu_x0fUCThioiT8nZ6PB0eJTESg2JzVQmEy0z66yRXikD5laVEzr1mbWGVVYzOxAOkvjces65MNpp74RUlhdCOOug03lGtuqm9juEpoZzxQcVY5g9wPxFF7nOGDyXFcqrrEferK1VXq4IOcoV9TIr0aIlWLRHPqEZOzlSaIcbzfV5GSOyhKmZs8i_ZI0R3FulpdS-KgqXKp1nVY_srZ2gjHHdlkwEH1SFul3cOSk0sxNDwKJNdO2bn6hCYQ6QM1DxfOVSXUM5zzm4ad4jcsPZNr5kU1JPLwIpuCzwkDLofBfc8p__phyejhlcX_y__a_JNoRX-fX45Msuuc8QyBOg6ntkC_zQv4RMbGFehRD7A3vVN7s
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Evaluation+of+the+safety+and+efficacy+of+using+human+menstrual+blood-derived+mesenchymal+stromal+cells+in+treating+severe+and+critically+ill+COVID-19+patients%3A+An+exploratory+clinical+trial&rft.jtitle=Clinical+and+translational+medicine&rft.au=Xu%2C+Xiaowei&rft.au=Jiang%2C+Wanli&rft.au=Chen%2C+Lijun&rft.au=Xu%2C+Zhenyu&rft.date=2021-02-01&rft.issn=2001-1326&rft.eissn=2001-1326&rft.volume=11&rft.issue=2&rft.spage=e297&rft_id=info:doi/10.1002%2Fctm2.297&rft_id=info%3Apmid%2F33634996&rft.externalDocID=33634996
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2001-1326&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2001-1326&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2001-1326&client=summon